Amicus Therapeutics Files 10-K, Confirms BioMarin Merger Progress with HSR Clearance and Strong 2025 Financials

summarizeSummary

Amicus Therapeutics' 10-K confirms the BioMarin acquisition is progressing with HSR clearance, alongside reporting strong 2025 financial results and key pipeline and patent updates.

check_boxKey Events

• BioMarin Acquisition Confirmed

  Reaffirms the definitive merger agreement with BioMarin Pharmaceutical Inc. for $14.50 per share in cash, with the transaction expected to close in Q2 2026. This follows the PREM14A filing on January 21, 2026, and DEFM14A on February 2, 2026.

• HSR Act Waiting Period Terminated

  The FTC granted early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period on February 11, 2026, satisfying a key regulatory condition for the merger's completion.

• Strong 2025 Financial Performance

  Reported audited full-year 2025 net product sales of $634.2 million, a 17% increase year-over-year, and a reduced net loss of $27.1 million, with positive net cash from operations of $33.1 million. This provides final details to the preliminary results announced in the 8-K on January 26, 2026.

• Dimerix License Agreement for Phase 3 Candidate

  Secured exclusive U.S. commercialization rights for Dimerix's Phase 3 FSGS drug candidate, DMX-200, with an upfront payment of $30 million, expanding the company's pipeline.

auto_awesomeAnalysis

This Annual Report on Form 10-K provides the definitive audited financial results for 2025, confirming strong revenue growth and a significant reduction in net loss. Crucially, it reiterates the pending acquisition by BioMarin Pharmaceutical Inc. for $14.50 per share and discloses the recent early termination of the HSR Act waiting period, a key regulatory milestone for the merger. The filing also details the Dimerix license agreement for a Phase 3 drug candidate and the settlement of patent litigation for Galafold, reinforcing the company's underlying business strength ahead of the acquisition.